GlassScriptPhysician profile
Sushant Wagley
NPI 1225481351
$6,344.83
in general payments reported to CMS, 2019-2025
6 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,802 · 2023: $63.06 · 2024: $2,237 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,115 · Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,115.00 |
| Food and Beverage | $428.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,901.45 | 2022-2024 | Vabysmo |
| Eyepoint US, INC. | $1,015.07 | 2022 | |
| Bausch & Lomb Americas INC. | $146.35 | 2023-2025 | Xipere |
| Alimera Sciences, INC. | $122.17 | 2024 | Iluvien, Yutiq |
| Tarsus Pharmaceuticals, INC. | $121.13 | 2025 | Xdemvy |
| Abbvie INC. | $38.66 | 2023 | Ozurdex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushant Wagley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.